Related Experiment Video
Updated: Jul 29, 2026
11:28
Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
Nitric oxide and its relationship to thrombotic disorders
1The Whitaker Cardiovascular Institute and Evans Department of Medicine, Boston University School of Medicine, 715 Albany Street, W507, Boston, MA 02118, USA. freedmaj@bu.edu
Journal of Thrombosis and Haemostasis : JTH
|July 23, 2003
Summary
Nitric oxide (NO) prevents platelets from sticking to blood vessel walls and forming clots. Impaired NO release is linked to diseases like atrial fibrillation and coronary artery disease.
Area of Science:
- Cardiovascular Biology
- Hemostasis and Thrombosis
- Endothelial Function
Background:
- Nitric oxide (NO) is a crucial signaling molecule produced by the endothelium.
- NO inhibits platelet aggregation and adhesion, playing a key role in preventing thrombosis.
- Reduced NO bioavailability is implicated in various cardiovascular diseases.
Purpose of the Study:
- To explore the role of endogenous nitric oxide (NO) in regulating thrombotic responses.
- To investigate the association between impaired NO release and clinical conditions characterized by thrombosis.
Main Methods:
- Review of existing literature on nitric oxide and thrombosis.
- Analysis of clinical data linking NO bioavailability to cardiovascular diseases.
Main Results:
- Endothelial NO release prevents platelet adhesion to the vessel wall.
- Platelet-derived NO inhibits the recruitment of additional platelets to thrombi.
- Clinical diseases such as atrial fibrillation and coronary atherothrombotic disease show impaired NO release or bioavailability.
Conclusions:
- Modulation of endogenous NO release represents a potential mechanism for regulating thrombotic responses.
- Impaired NO bioavailability is a significant factor in the pathogenesis of thrombotic disorders.
- Understanding NO's role is critical for developing therapeutic strategies for cardiovascular diseases.
Related Concept Videos
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...